Cargando…

Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States

BACKGROUND: Real-world data on usage and associated outcomes with hereditary angioedema (HAE)-specific medications introduced to the United States (US) market since 2009 are very limited. The purpose of this retrospective study was to evaluate real-world treatment patterns of HAE-specific medication...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riedl, Marc A, Banerji, Aleena, Manning, Michael E, Burrell, Earl, Joshi, Namita, Patel, Dipen, Machnig, Thomas, Tai, Ming-Hui, Watson, Douglas J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186115/ https://www.ncbi.nlm.nih.gov/pubmed/30314518 http://dx.doi.org/10.1186/s13023-018-0922-3

Ejemplares similares

Optimal Management of Hereditary Angioedema: Shared Decision-Making
por: Banerji, Aleena, et al.
Publicado: (2021)

Consider Hereditary Angioedema in the Differential Diagnosis for Unexplained Recurring Abdominal Pain
por: Staller, Kyle, et al.
Publicado: (2022)

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
por: Johnston, Douglas T., et al.
Publicado: (2021)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021)

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021)

Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
por: Feussner, Annette, et al.
Publicado: (2014)

Correction to: Mitigating Disparity in Healthcare Resources Between Countries for Management of Hereditary Angioedema
por: Jindal, Ankur Kumar, et al.
Publicado: (2021)

Expert perspectives on hereditary angioedema: Key areas for advancements in care across the patient journey
por: Banerji, Aleena, et al.
Publicado: (2016)

Hereditary Angioedema Therapy: Kallikrein Inhibition and Bradykinin Receptor Antagonism
por: Riedl, Marc
Publicado: (2010)

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema
por: Craig, Timothy, et al.
Publicado: (2017)

Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene
por: Bork, Konrad, et al.
Publicado: (2020)

Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks
por: Bernstein, Jonathan A., et al.
Publicado: (2019)

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
por: Li, H. Henry, et al.
Publicado: (2019)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema
por: Riedl, Marc
Publicado: (2015)

Recognition and Management of Hereditary Angioedema: Best Practices for Dermatologists
por: Manning, Michael E.
Publicado: (2021)

Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence
por: Bork, Konrad, et al.
Publicado: (2020)

Hereditary angioedema in women
por: Bouillet, Laurence
Publicado: (2010)

Hereditary Angioedema: Not An Allergy
por: Bhivgade, Sanjay, et al.
Publicado: (2012)

The Pathophysiology of Hereditary Angioedema
por: Zuraw, Bruce L
Publicado: (2010)

Pediatric hereditary angioedema
por: MacGinnitie, Andrew J
Publicado: (2014)

Hereditary angioedema in childhood
por: Ahn, Young Min
Publicado: (2020)

Lanadelumab for hereditary angioedema
Publicado: (2022)

Biomarkers in Hereditary Angioedema
por: Porebski, Grzegorz, et al.
Publicado: (2021)

The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2019)

Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema
por: Zhang, Ying, et al.
Publicado: (2018)

Hereditary Angioedema Consensus 2010
por: Bowen, Tom
Publicado: (2010)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Bradykinin and the Pathogenesis of Hereditary Angioedema
por: Kaplan, Allen P
Publicado: (2011)

The Search for Biomarkers in Hereditary Angioedema
por: Kaplan, Allen P., et al.
Publicado: (2017)

Improving the Management of Hereditary Angioedema
por: Giavina-Bianchi, Pedro, et al.
Publicado: (2018)

Pediatric hereditary angioedema: an update
por: Sabharwal, Geetika, et al.
Publicado: (2017)

Are pediatricians familiar with hereditary angioedema?
por: Chong-Neto, Herberto José, et al.
Publicado: (2023)

Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States
por: Lo, Siu Hing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vv6u355utd27eojp5rhjpe3bcf